WO2002020005A1 - Utilisation de l'arginine pour l'endoscopie et d'autres actes medicaux - Google Patents

Utilisation de l'arginine pour l'endoscopie et d'autres actes medicaux Download PDF

Info

Publication number
WO2002020005A1
WO2002020005A1 PCT/GB2001/004014 GB0104014W WO0220005A1 WO 2002020005 A1 WO2002020005 A1 WO 2002020005A1 GB 0104014 W GB0104014 W GB 0104014W WO 0220005 A1 WO0220005 A1 WO 0220005A1
Authority
WO
WIPO (PCT)
Prior art keywords
arginine
derivative
region
procedure
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2001/004014
Other languages
English (en)
Inventor
Norman Barras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Norgine Europe BV
Original Assignee
Norgine Europe BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2000/004017 external-priority patent/WO2001028538A2/fr
Application filed by Norgine Europe BV filed Critical Norgine Europe BV
Priority to AU2001284294A priority Critical patent/AU2001284294A1/en
Publication of WO2002020005A1 publication Critical patent/WO2002020005A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Definitions

  • the present invention relates to improvements to in vivo procedures, especially endoscopy.
  • the present invention is concerned with procedures carried out on internal regions of the body that comprise muscle, both smooth muscle and striated muscle. Such procedures are in particular procedures carried out on tracts, tubes, canals, cavities and organs that comprise muscle, for example, the vagina, cervix, uterus and Fallopian tubes, the urethra, ureter and bladder, and especially the gastrointestinal tract (GI tract) .
  • GI tract gastrointestinal tract
  • In vivo investigative techniques include radiography, ultrasound, CT and NMR scans, and endoscopy.
  • the general techniques are well known, as are specialised applications, for example, angiography and digital subtraction angiography.
  • contrast media are used to enhance the visualisation of the target site. All of the techniques are diagnostic. Some, in particular endoscopy, also enable biopsy samples to be obtained and therapeutic and surgical procedures, to be carried out during the investigation.
  • the term "procedure” as used herein includes investigations and other procedures that are diagnostic and therapeutic and surgical procedures, including biopsy, which are carried out in si tu .
  • a procedure may be exclusively investigative, therapeutic or surgical or may involve any combination thereof .
  • a medical problem often encountered by a person carrying out an in vivo procedure on a region of the body that comprises muscle is that of motility. Movement of muscle, for example, muscular tissue or a muscular organ, at or near the site of a procedure reduces the effectiveness of the procedure.
  • GI tract gastrointestinal tract
  • motility a natural motility associated with the GI tract. It is generally described as movement of the muscular component of the digestive tube, and includes peristalsis and segmentation.
  • the natural motility of the GI tract may cause difficulties, for example, in entering sphincters, in passing the endoscope through the tract or both. Contraction of a sphincter may make it difficult to pass an endoscope through the sphincter. If the natural motility of the GI tract is increased, for example, by one or more of fasting, the use of bowel preparations and the presence of disease, the problems are increased. Furthermore, during an endoscopic procedure, the presence of the endoscope itself may cause the gut, including sphincters, to contract, which causes difficulties, for example, for any one or more of the following: further passage of the endoscope, visualisation, and manipulations.
  • Buscopan (Trade Mark) comprises hyoscine butylbromide, an anticholinergic agent. It frequently causes side effects, for example, cramps, meteorism, pain, tachycardia and urine retention, and its use should be avoided in patients with glaucoma and prostate pathology.
  • Glucagon available under the Trade Mark Glucagen, is normally used as a treatment of hypoglycae ic episodes, but has also been used to reduce gastric tract motility, which use frequently results in nausea and vomiting.
  • the present invention provides a method for carrying out a procedure on an internal region of the body of a human subject, which internal region comprises muscle, which method comprises administering to part or all of the region an amount of the amino acid arginine, a derivative thereof, or a pharmaceutically acceptable salt of arginine or a derivative thereof effective to cause muscle in the treated region to relax, and carrying out the procedure while the muscle in the treated region is relaxed.
  • the present invention provides a method for carrying out a procedure on an internal region of the body of a human subject, which internal region comprises muscle, which method comprises administering to part or all of the region an amount of the amino acid arginine, a derivative thereof, or a pharmaceutically acceptable salt of arginine or a derivative thereof effective to reduce the motility of the treated region, and carrying out the procedure while the motility of the treated region is reduced.
  • the present invention provides a method for carrying out a procedure on an internal region of the body of a human subject, which internal region comprises muscle, which method comprises administering an effective amount of the amino acid arginine, a derivative thereof, or a pharmaceutically acceptable salt of arginine or a derivative thereof, to part or all of the region, allowing muscle in the treated region to relax, and carrying out the procedure while the muscle in the treated region is relaxed.
  • the present invention provides a method for carrying out a procedure on an internal region of the body of a human subject, which internal region comprises muscle, which method comprises administering an effective amount of the amino acid arginine, a derivative thereof, or a pharmaceutically acceptable salt of arginine or a derivative thereof, to part or all of the region, allowing the motility of the treated region to reduce, and carrying out the procedure while the motility of the treated region is reduced.
  • the present invention provides use of the amino acid arginine, a derivative thereof, or a pharmaceutically acceptable salt of arginine or a derivative thereof for the manufacture of a medicament for use in a method for carrying out a procedure on an internal region of the body of a human subject, which internal region comprises muscle, which method comprises administering the amino acid arginine, a derivative thereof, or a pharmaceutically acceptable salt of arginine or a derivative thereof to part or all of the region in an amount sufficient to cause muscle in the treated region to relax, and carrying out the procedure while the muscle in the treated region is relaxed.
  • the present invention provides use of the amino acid arginine, a derivative thereof, or a pharmaceutically acceptable salt of arginine or a derivative thereof for the manufacture of a medicament for use in a method for carrying out a procedure on an internal region of the body of a human subject, which internal region comprises muscle, which method comprises administering the amino acid arginine, a derivative thereof, or a pharmaceutically acceptable salt of arginine or a derivative thereof to part or all of the region to be treated in an amount sufficient to reduce the motility of the treated region, and carrying out the procedure while the motility of the treated region is reduced.
  • the present invention provides use of the amino acid arginine, a derivative thereof, or a pharmaceutically acceptable salt of arginine or a derivative thereof for the manufacture of a medicament for use in a method for carrying out a procedure on an internal region of the body of a human subject, which internal region comprises muscle, which method comprises administering the amino acid arginine, a derivative thereof, or a pharmaceutically acceptable salt of arginine or a derivative thereof, to part or all of the region, allowing muscle in the treated region to relax, and carrying out the procedure while the muscle in the treated region is relaxed.
  • the present invention provides use of the amino acid arginine, a derivative thereof, or a pharmaceutically acceptable salt of arginine or a derivative thereof for the manufacture of a medicament for use in a method for carrying out a procedure on an internal region of the body of a human subject, which internal region comprises muscle, which method comprises administering the amino acid arginine, a derivative thereof, or a pharmaceutically acceptable salt of arginine or a derivative thereof, to part or all of the region, allowing the motility of the treated region to reduce, and carrying out the procedure while the motility of the treated region is reduced.
  • the present invention provides a method for reducing motility and/or for causing relaxation of muscle in an internal region of the body of a human subject, which internal region comprises muscle, during an in vivo procedure involving said region, which comprises administering to part or all of said region, before or during the procedure, an effective amount of the amino acid arginine, a derivative thereof, or a pharmaceutically acceptable salt of arginine or a derivative thereof, generally in admixture with a pharmaceutically acceptable carrier.
  • the present invention also provides a method for facilitating an in vivo procedure on an internal region of the body of a human subject, which internal region comprises muscle, wherein there is administered to part or all of the region, before or during the procedure, an effective amount of the amino acid arginine, a derivative thereof, or a pharmaceutically acceptable salt of arginine or a derivative., thereof, generally in admixture with a pharmaceutically acceptable carrier.
  • the present invention also provides the use of arginine, a derivative thereof, or a pharmaceutically acceptable salt of arginine or a derivative thereof, for the manufacture of a medicament for use in a method for reducing motility and/or causing relaxation of muscle in an internal region of the body of a human subject, which internal region comprises muscle, during an in vivo procedure involving the internal region, which method comprises administering the arginine, derivative thereof, or pharmaceutically acceptable salt to part or all of the region, before or during the procedure.
  • the present invention also provides the use of arginine, a derivative thereof, or a pharmaceutically acceptable salt of arginine or a derivative thereof for the manufacture of a medicament for use in a method for facilitating an in vivo procedure on a region of the body of a human subject, which internal region comprises muscle, which method comprises administering the arginine, derivative thereof, or pharmaceutically acceptable salt to part or all of the internal region, before or during the procedure.
  • the arginine, derivative thereof or pharmaceutically acceptable salt is administered to the region before the in vivo procedure is carried out, it must be administered at such a time before the procedure that, when the procedure is carried out muscle in the region is relaxed, motility in the region is reduced, or both.
  • the arginine, derivative thereof, or pharmaceutically acceptable salt facilitates the in vivo procedure by reducing motility of muscle or causing relaxation of muscle, or both of the region of the body undergoing the procedure.
  • the in vivo procedure may be investigative, therapeutic or surgical, or may involve any combination thereof.
  • arginine active substance is used herein to denote arginine, derivatives thereof and pharmaceutically acceptable salts of arginine and of derivatives thereof. Examples of derivatives and salts are given below.
  • the arginine may be L- arginine, D-arginine or a mixture thereof.
  • Derivatives and pharmaceutically acceptable salts of arginine and of arginine derivatives are derivatives and salts of L-arginine, D- arginine or a mixture thereof .
  • An effective amount of an arginine active substance is an amount that results in at least partial reduction in motility or at least partial relaxation of muscle.
  • the muscle may be smooth muscle, or striated muscle, and may be a sphincter.
  • references to relaxation of muscle denote at least partial relaxation.
  • References to reduction of motility denote at least partial reduction in motility.
  • Complete relaxation of muscle or reduction in motility may be produced by administration of the arginine active substance, but in most cases complete relaxation of muscle or reduction in motility is not necessary and partial relaxation of muscle or reduction in motility is sufficient for the present invention .
  • the arginine active substance is administered locally, not systemically .
  • the arginine active substance is delivered to all or part of the region of the body where the procedure is carried out. It will be understood that administration to all or part of a region of the body means administration to appropriate parts of the body in that region.
  • the invention further provides the use or method according to the invention wherein the subject is a non-human animal other than a rodent.
  • the subject is selected from the group consisting of animals used in food production, breeding animals, companion animals, horses, cats and dogs.
  • the region of the body involved in an in vivo procedure is generally greater than the specific site that is the target of the procedure.
  • the site under investigation is the bile ducts.
  • the endoscope is passed from the mouth through the stomach to the duodenum, then to the sphincter of oddi and optionally through the sphincter and into the bile ducts.
  • the region of the body involved in the endoscopic procedure therefore includes more of the GI tract than just the site that is the specific target for investigation ie the bile ducts themselves. It includes the region of the GI tract from the mouth to the bile ducts.
  • the arginine active substance may be administered to any part or to all of the region involved in the procedure, which region comprises muscle.
  • the region involved in the procedure is the region of the GI tract from the mouth to the bile ducts themselves, which region comprises muscle.
  • the arginine active substance may be administered to any part of that region or to all of that region. Further details are given below.
  • the same considerations apply to procedures involving other regions of the body that comprise muscle.
  • the site of investigation or surgery is the Fallopian tubes themselves, but the region of the body involved in the procedure includes the vagina, the cervix, the uterus and the Fallopian tubes themselves.
  • the region of the body involved in the procedure includes the urethra, the bladder and the ureter. Both of these regions comprise muscle.
  • the arginine active substance may be applied to part or to all of the region involved in the procedure .
  • the same considerations also apply to other types of procedures, for example, other in vivo investigative procedures, for example, radiographic procedures, for example, angiography, for example, digital subtraction angiography, ultrasound investigations, and CT and NMR scans.
  • the arginine active substance may be administered to the appropriate region or to part of the region.
  • the arginine active substance may be applied to all or part of the GI tract before administration of the contrast medium and carrying out the radiological investigation.
  • the region involved in the procedure is the abdomen, which includes the GI tract, movement of which can impair the investigation.
  • the arginine active substance may be administered to all or part of the GI tract before the ultrasound investigation to reduce the motility of the gut and hence improve visualisation of the organ under investigation.
  • the arginine active substance must be administered at such a time before the investigative procedure that muscle in the region is relaxed and/or motility is reduced when the investigation is carried out.
  • the procedure in question involves an internal region of the body, the measurements themselves may be recorded from outside of the body. This may be the case, for example, for an ultrasound scan.
  • the present invention is concerned with investigations and therapeutic and surgical procedures carried out on internal regions of the body that comprise muscle.
  • the invention is particularly concerned with investigations, surgery and therapeutic procedures carried out on tracts, tubes, canals, cavities and organs that comprise muscle, for example, procedures, especially endoscopy, carried out on the vagina, cervix, uterus and Fallopian tubes, of the urethra, ureter and bladder, and especially of the gastrointestinal tract (GI tract) .
  • GI tract gastrointestinal tract
  • the present invention may be regarded as an aid to in vivo diagnostic investigations and to therapeutic and surgical procedures when diminished motility is required, especially in examination procedures and therapeutic and surgical, procedures carried out on the oesophagus, stomach, duodenum, small bowel and colon, particularly investigations involving radiological examination and also ultrasound, CT and NMR scans .
  • Endoscopy is a general technique for inspection of internal cavities using an endoscope, which is generally a flexible fibre-optic device, that both illuminates and enables inspection of the desired site.
  • An endoscope may also comprise further means, for example, for administering a contrast agent .
  • An endoscope may be used for carrying out biopsy or a surgical procedure, or both biopsy and surgery may be carried out during the same procedure.
  • the use of endoscopy has increased greatly in recent years with miniaturisation of and improvements in optical devices including cameras and surgical instrumentation used with endoscopes . Endoscopes now enable effective visualisation of a variety of internal cavities and hence effective diagnosis and surgery .
  • Endoscopy may be non-invasive, the endoscope being inserted into the body through a natural orifice, or it may be invasive, the endoscope being inserted through a surgical incision.
  • the present invention is particularly concerned with endoscopy of tracts, tubes, canals, cavities and organs that comprise muscle, for example, endoscopy of the vagina, cervix, uterus and Fallopian tubes, of the urethra, ureter and bladder, and especially of the gastrointestinal tract (GI tract) .
  • GI tract gastrointestinal tract
  • Endoscopy of the upper part of the GI tract including the oesophagus, stomach, duodenum, sphincter of oddi, pancreatic and bile ducts is carried out per os .
  • Endoscopy of the lower GI tract including the anus, rectum, colon and ileum is carried out per anal canal.
  • Endoscopy of certain regions of the GI tract is often referred to by specific terms.
  • colonoscopy is endoscopy of the colon
  • sigmoidoscopy is endoscopy of the sigmoid colon
  • proctoscopy is endoscopy of the anal canal and rectum.
  • Endoscopic retrograde cholangiopancreatography (ERCP) is endoscopy of the pancreatic and bile ducts via the sphincter of oddi.
  • ERCP a flexible endoscope is passed through the mouth and down into the duodenum.
  • a catheter is then passed through the endoscope and inserted via the sphincter of oddi into the pancreatic or bile ducts.
  • a contrast agent is injected into the catheter, which agent highlights the course and calibre of the duct. Narrowing, stones or ductal tumours can be identified using this procedure.
  • Therapeutic and surgical measures can also be undertaken at the time of ERCP to remove stones in the bile ducts or to relieve obstructions in the bile ducts, so that traditional open surgery can be avoided.
  • ERCP is increasingly accepted as the diagnostic, therapeutic and surgical procedure of choice, for example, in identifying and removing gallstones in the bile duct.
  • the invention includes endoscopic procedures and also other in vivo investigative procedures, for example, other radiographic techniques, for example, angiography, for example, digital subtraction angiography, and ultrasound investigations, CT and NMR scans.
  • the arginine active substance may be administered to the desired region or part of a region by whatever means is most appropriate.
  • the active substance may be administered, for example, via a catheter or pessary or by local application, for example, in the form of a cream gel or foam; for investigations of the urinary tract the active substance is generally administered via a catheter.
  • the arginine active substance is administered before the procedure is carried out, it must be administered at such a time that muscle in the region is relaxed and/or motility in the region is reduced at the time when the procedure is carried out.
  • the individual subjected to the procedure is generally a mammal and is especially a human.
  • the internal region of the body undergoing the endoscopic procedure is, for example, a tract, tube, canal, cavity or organ that comprises muscle.
  • the endoscopic procedure may be, for example, endoscopy of the vagina, cervix, uterus and
  • Fallopian tubes for example hysteroscopy, the examination of the inner cavity of the uterus through a fibre optic telescope inserted through the vagina and cervical canal
  • Fallopian tubes for example hysteroscopy, the examination of the inner cavity of the uterus through a fibre optic telescope inserted through the vagina and cervical canal
  • an endoscopic procedure on a particular site in the body generally involves a larger region that includes the specific site that is under investigation.
  • site of the endoscopic procedure is the pancreatic or bile ducts.
  • an endoscope is passed from the mouth through the stomach to the duodenum.
  • the region of the body involved in the ERCP endoscopic procedure therefore includes more of the GI tract than just the site that is the specific target for investigation, that is to say, the pancreatic and bile ducts. It also includes the region of the GI tract from the mouth to the duodenum.
  • the arginine active substance may be administered to all or part of the region of the body that is to undergo the chosen procedure.
  • the arginine active substance may be applied directly to any one or more sites selected from the sphincter of oddi, the pancreatic ducts and the bile ducts, to improve visualisation of and passage through those sites.
  • the arginine active substance may be applied to other parts of the upper GI tract to assist the insertion of the endoscope or any other tubing through those parts of the region en route to the target site.
  • the arginine active substance is advantageously administered directly to the desired region via the endoscope itself or via a separate catheter.
  • the active substance can be sprayed from the endoscope or other catheter.
  • Many endoscopes comprise an integral working canal, for example, for the administration of a contrast agent or to enable air to be blown down to clear an area to assist passage of the endoscope or to improve visibility.
  • the present invention relates, for example, to surgery.
  • the invention relates to surgery on an internal organ comprising muscle wherein one or more of reduction in motility and muscle relaxation is desirable.
  • the invention also relates to surgery in the abdominal cavity wherein one or more of relaxation of muscle and reduction in motility, for example the gut, assists the surgical procedure. If the arginine, derivative thereof or pharmaceutically acceptable salt is administered before the surgery is carried out, it must be administered to the relevant region at such a time before surgery that, when the surgery is carried out, muscle in the region is relaxed, motility in the region is reduced or both.
  • the invention relates especially to surgery on the gut, but also to surgery on other abdominal organs, for example the female reproductive tract.
  • the arginine active substance may be administered to all or part of the appropriate region.
  • the arginine active substance may be administered to all or part of that region of the body, for example, to any one or more of the vagina, the cervix, the uterus and the Fallopian tubes, or to a part thereof.
  • the arginine active substance may be administered to all or part of the relevant region, for example to any one of more of the urethra, the bladder and the ureters, or to a part thereof.
  • the arginine active substance may be administered continuously during a procedure or as required.
  • the latter is particularly useful in the case of endoscopy of the GI tract or other regions of the body as the investigator carrying out the endoscopy can readily determine during the procedure where and when motility is interfering adversely with the procedure .
  • Administration as required during a procedure is particularly useful in procedures involving the bile or pancreatic ducts, as the endoscope can be positioned suitably and the arginine active substance administered directly on to the sphincter of oddi, duodenal regions around the sphincter of oddi and/or into the ducts, greatly improving visualisation and passage of the apparatus, and also enabling biopsy and surgical manipulations.
  • Administration of L-arginine directly to the duodenum gives a relaxation of the duodenum of up to about 60 minutes and enables a very clear view of, for example, the duodenum, sphincter of oddi and pancreatic and bile ducts.
  • arginine active substance is applied to other parts to the GI tract, for example, directly to the colon during colonoscopy.
  • An alternative to direct administration is administration of the arginine active substance by a route and using a formulation that will result in release of the active substance at the appropriate region.
  • a formulation that will result in release of the active substance at the appropriate region.
  • an oral pharmaceutical preparation that releases the active substance either substantially throughout the GI tract or that releases the active substance in a targeted manner at or near a specific region, for example, at or near the duodenum in the case of ERCP.
  • Targeted delivery may be achieved using an appropriate coated or otherwise delayed release or targeted release pharmaceutical composition, for example, a tablet or capsule.
  • Formulations for delayed and targeted release are known in the art.
  • the arginine active substance When the arginine active substance is administered before the procedure is carried out, it must be administered at such a time that muscle in the region is relaxed and/or motility in the region is reduced at the time when the procedure is carried out.
  • the active substance may be administered, for example, via a catheter or pessary or by local application, for example, in the form of a cream gel or foam; for investigations of the urinary tract the active substance is generally administered via a catheter.
  • the arginine active substance when administered before the procedure is carried out, it must be administered at such a time that muscle in the region is relaxed and/or motility in the region is reduced at the time when the procedure is carried out.
  • the arginine active substance may be arginine itself, a pharmaceutically acceptable salt thereof, a derivative of arginine or a pharmaceutically acceptable salt of a derivative.
  • the arginine may be L-arginine, D-arginine or a mixture thereof .
  • Examples of pharmaceutically acceptable salts of arginine include, arginine monohydrocholoride, arginine free base, arginine aspartate salt, glutamyl arginine, arginine hydrochloride, arginine hydroxamate, arginine phosphate, argininic acid, arginine benzylidene, arginine diflavinate, arginine dipicrate and arginine picrate.
  • the hydrochloride salt is particularly preferred.
  • a salt may be of L-arginine or D-arginine or of a mixture thereof.
  • Derivatives of arginine include, for example, esters, amides, carboxamido derivatives, amines, imines and imides. Esters and amides may be formed at the terminal carboxy group, and carboxamido derivatives, amines, imines and imides at the alpha (peptide forming) amino group or at the guanidino group. Pharmaceutically acceptable salts of arginine derivatives are, for example, as described above for arginine itself. Esters may be formed with aliphatic, aryl or heteroaryl groups.
  • esters include alkyl esters having from 1 to 4 carbon atoms in the alkyl moiety, for example, L-arginine methyl ester and the dihydrochloride thereof, L-arginine ethyl ester and the dihydrochloride thereof, and esters with arylsulphonic acids, for example with p-toluene sulphonic acid, for example the L-arginine methyl ester p-toluenesulfonyl derivative.
  • Further derivatives include those with carboxylic acids, for example, argininosuccinic acid, and derivatives with polyhydroxy compounds, for example, with saccharides, for example, ' polysaccharides, for example, L-arginine agarose.
  • L-arginine amides and derivatives and salts thereof include, for example, L-argininamide and the dihydrochloride thereof, L- arginin-IS ⁇ -amine and salts thereof, for example, the flavionate salt thereof, and amides formed with alkyl groups, especially those having from 1 to 4 carbons atoms, and with aryl and heteroaryl groups, for example, with naphthyl and substituted naphthyl groups, for example, alkyl and alkoxy, especially Cl-C4-alkyl- and Cl-C4-alkoxy-substituted naphthyl groups, and salts thereof, for example, L-arginine-4-methoxy- ⁇ -naphthylamide, L-arginine- ⁇ -naphthylamide and the hydrochloride thereof, and with nitroaniline, for example, L- arginine-p-nitroanilide and the dihydrochloride thereof.
  • the active substance is administered locally, not systemically.
  • the active substance is delivered to all or part of the region of the body involved in the procedure.
  • the arginine active substance may be delivered via the endoscope itself or via another catheter, which ensures delivery at the correct site and also enables delivery when and where required.
  • An example of a preparation suitable for administration via an endoscope or via another catheter to the desired site is a solution or suspension of the arginine active substance in a pharmaceutically suitable liquid carrier, for example, in water, preferably water for injection, or a physiological saline, for example phosphate buffered saline or normal saline.
  • a liquid preparation may be thickened to assist its retention at the desired site, for example, using hydroxy methyl cellulose or another appropriate thickening agent.
  • the concentration of the arginine active substance in a liquid carrier may be determined on the basis of the desired total dose and an appropriate volume of liquid for the intended administration. For example, for administration to the duodenum or other parts of the GI tract a volume of up to about 150 ml, for example, up to about 100 ml may be used. The volume is generally greater than 5 ml, for example, greater than 10 ml. For example, from 20 to 40 ml of liquid carrier may be used.
  • Appropriate concentrations of arginine in a liquid carrier are, for example, 50 mg/ml or more, for example, 100 mg/ml or more, for example, 150 mg/ml or more, for example, 200 mg/ml or more, for example, 500 mg/ml or more. Generally at least 50 mg/ml will be used, for example, at least 100 mg/ml, for example, at least 150 mg/ml.
  • Equivalent amounts of an arginine salt or an arginine derivative or pharmaceutically acceptable salt thereof should be used, that is to say, the amount of the derivative or salt should be such that amount of arginine provided is as set out above .
  • the total dose of the arginine active substance to be administered may be, for example, from 0.5 g to 20 g, for example, from 1 to 10 g for example, from 2 to 8 g, for example, from 3 to 6 g of arginine or the equivalent amount of a derivative or salt thereof,
  • arginine active substance The dosages and concentrations of arginine active substance mentioned above apply to arginine for application to a subject.
  • the arginine active substance may however be provided in a more concentrated form and such a concentrate may be diluted to the desired concentration with saline, water or other carrier prior to use.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising arginine active substance in solution in a pharmaceutically suitable solvent, for example saline or water.
  • a pharmaceutically suitable solvent for example saline or water.
  • the solution may contain a thickener and, more especially, the solution may be in the form of a concentrate for the manufacture of the final composition to be administered.
  • a concentrate may comprise arginine at a concentration of at least 500 mg/ml and may be a saturated solution.
  • the invention further provides a solution for use in the treatment of a human subject, more especially in a method of the invention .
  • the arginine active substance may also be administered in the form of a preparation that is suitable for oral ingestion.
  • the preparation may be a tablet, capsule or powder.
  • the tablet or capsule is coated with an enteric coating that is selected so that it dissolves at a desired location in the gastrointestinal tract, for example, at the duodenum.
  • enteric coatings are known. Many of these take the form of pH sensitive polymers. The polymer is coated onto the surface of the tablet and the product is released only after the coating has dissolved.
  • Enteric coatings that may be used in conjunction with the formulations of the invention include, for example, cellulose acetate 1,2 benzedi- carboxylate, hexadecan-1-ol, cellulose ethyl ether, liquid glucose, cellulose 2-hydroxyethylether, cellulose 2- hydroxypropylether , cellulose 2-hydroxypropyl methyl ether, cellulose hydrogen 1,2 benzene dicarboxylate 2- hydroxypropylmethyl ether, maltodextrin, cellulose methylether, polymethacrylates, shellac, confectioner's sugar, titanium oxide, carnauba wax, microcrystalline wax, zein, gelatin, polyvinyl ethanol and cellulose carboxymethyl ether sodium salt. It is also possible to blend the arginine active substance with a polymer before coating the tablet. In this case the active ingredient is released at the desired location and sustained or controlled release of the drug at the site can be achieved.
  • Drug delivery systems that are colon specific may also be used in conjunction with the present invention in order to effect release of the drug in the colon.
  • Drug delivery systems are known that effect selective targeting to the ascending, transverse or descending sections of the colon.
  • coatings are known that are degraded by colonic bacteria.
  • the amount of the arginine, derivative thereof or pharmaceutically acceptable salt thereof administered is preferably such that an effective quantity of the active substance reaches the rectum, anus or colon. In a preferred embodiment, from 0.1 mg to 5 g of arginine reach the rectum, anus or colon, more preferably from 10 mg to 1 g reach the rectum, anus or colon, still more preferably 50 mg to 800 mg reach the rectum, anus or colon.
  • the requisite amount of the arginine active substance reaches the descending colon or the rectum.
  • the pharmaceutically acceptable carrier is an enema solution.
  • the amount of the arginine present in a preparation for oral administration should be such that an effective amount is delivered to the desired site. Preferred doses of the arginine active substance are set out above. When the arginine active substance is administered before the procedure is carried out, it must be administered at such a time that muscle in the region is relaxed and/or motility in the region is reduced at the time when the procedure is carried out.
  • the present invention has been described in detail above in relation to endoscopy of the GI tract.
  • the teachings may be applied, mutatis mutandis, to other endoscopic procedures and also to other in vivo investigative procedures, for example, other radiographic techniques, for example, angiography, for example, digital subtraction angiography, and to ultrasound investigations, CT and NMR scans.
  • the arginine active substance may be administered to the desired region or part of a region by whatever means is most appropriate.
  • the arginine active substance may be administered, for example, via a catheter or oral preparation, for example, as described above; for investigations of the female reproductive tract the active substance may be administered, for example, via a catheter or pessary or by local application, for example, in the form of a cream gel or foam; for investigations of the urinary tract the active substance is generally administered via a catheter.
  • the subject undergoing the procedure is generally a human but, in a variant of the invention, may be another animal other than a rodent, especially a mammal other than a rodent.
  • a mammal may be a commercially reared animal, especially a non-laboratory animal, for example, a bovine or ovine animal or a horse, or may be a companion animal or a pet, for example a cat or a dog. It may also be a sports animal or an animal reared in a zoo.
  • a commercially reared animal may be reared for its meat or milk, for its coat or skin, or for breeding, for example a key stud animal.
  • the motility of the duodenum was seen to be either reduced, diminished or stopped i.e. was not observed.
  • the passage of the endoscope tube through the sphincter of oddi was described by the investigator as "easy” or "not difficult”.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une méthode pour faciliter un acte médical in vivo réalisé dans une région interne du corps d'un patient, cette région comportant un muscle. Selon cette méthode, avant ou pendant l'acte médical, on administre, à une partie de ladite région ou à la totalité de celle-ci, de l'arginine, un dérivé de cette dernière, ou un sel pharmaceutiquement acceptable de l'arginine, généralement dans un support pharmaceutiquement acceptable. La présente invention porte également sur l'utilisation de l'arginine, d'un dérivé de celle-ci ou d'un sel pharmaceutiquement acceptable de cette dernière pour la production d'un médicament destiné à cet usage dans le cadre d'une telle méthode. L'acte médical peut être exécuté à des fins diagnostiques et/ou thérapeutiques, et peut, par exemple, être chirurgical. Les actes médicaux comprennent l'endoscopie, la radiographie, les ultrasons, la tomographie par ordinateur et l'IRM. En réduisant la motilité et/ou en provoquant la détente des muscles, l'arginine facilite ainsi l'acte médical.
PCT/GB2001/004014 2000-09-06 2001-09-06 Utilisation de l'arginine pour l'endoscopie et d'autres actes medicaux Ceased WO2002020005A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001284294A AU2001284294A1 (en) 2000-09-06 2001-09-06 Use of arginine in endoscopy and other medical procedures

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0021876.8 2000-09-06
PCT/GB2000/004017 WO2001028538A2 (fr) 1999-10-18 2000-10-18 Preparation d'un laxatif

Publications (1)

Publication Number Publication Date
WO2002020005A1 true WO2002020005A1 (fr) 2002-03-14

Family

ID=9886074

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/004014 Ceased WO2002020005A1 (fr) 2000-09-06 2001-09-06 Utilisation de l'arginine pour l'endoscopie et d'autres actes medicaux

Country Status (1)

Country Link
WO (1) WO2002020005A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946258B1 (en) * 2011-02-10 2015-02-03 Jugal K. Taneja Methods of non-gastrointestinal endoscopic procedures using L-hyoscyamine oral formulations
US9155731B1 (en) * 2011-02-10 2015-10-13 Jugal K Taneja Methods of non-gastrointestinal endoscopic procedures using L-hyoscyamine oral formulations
US12383700B2 (en) 2019-06-13 2025-08-12 Hollister Incorporated Reusable urinary catheter products
US12440644B2 (en) 2019-06-25 2025-10-14 Hollister Incorporated Reusable urinary catheter products

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595753A (en) * 1995-04-14 1997-01-21 President And Fellows Of Harvard College Topical formulations and methods for treating hemorrhoidal pain and sphincter and smooth muscle spasm in the gastrointestinal tract
US5827889A (en) * 1996-04-23 1998-10-27 Robert Cunico Anal fissure treatment preparation and method
US5958881A (en) * 1991-04-25 1999-09-28 Korman; Louis Y. Composition containing VIP for injection and a method of enhancing visualization of tissues during medical procedures
US6063027A (en) * 1994-11-30 2000-05-16 Aerocrine Ab Diagnostic method for inflammatory conditions in the intestines
WO2001028538A2 (fr) * 1999-10-18 2001-04-26 Norgine Research Limited Preparation d'un laxatif

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958881A (en) * 1991-04-25 1999-09-28 Korman; Louis Y. Composition containing VIP for injection and a method of enhancing visualization of tissues during medical procedures
US6063027A (en) * 1994-11-30 2000-05-16 Aerocrine Ab Diagnostic method for inflammatory conditions in the intestines
US5595753A (en) * 1995-04-14 1997-01-21 President And Fellows Of Harvard College Topical formulations and methods for treating hemorrhoidal pain and sphincter and smooth muscle spasm in the gastrointestinal tract
US5827889A (en) * 1996-04-23 1998-10-27 Robert Cunico Anal fissure treatment preparation and method
WO2001028538A2 (fr) * 1999-10-18 2001-04-26 Norgine Research Limited Preparation d'un laxatif

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DOKITA S ET AL: "NG-NITRO-L-ARGININE INHIBITS NON-ADRENERGIC, NON-CHOLINERGIC RELAXATION IN RABBIT URETHRAL SMOOTH MUSCLE", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 48, no. 25, 1991, pages 2429 - 2436, XP000670051, ISSN: 0024-3205 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946258B1 (en) * 2011-02-10 2015-02-03 Jugal K. Taneja Methods of non-gastrointestinal endoscopic procedures using L-hyoscyamine oral formulations
US9155731B1 (en) * 2011-02-10 2015-10-13 Jugal K Taneja Methods of non-gastrointestinal endoscopic procedures using L-hyoscyamine oral formulations
US12383700B2 (en) 2019-06-13 2025-08-12 Hollister Incorporated Reusable urinary catheter products
US12440644B2 (en) 2019-06-25 2025-10-14 Hollister Incorporated Reusable urinary catheter products

Similar Documents

Publication Publication Date Title
Robertson et al. Effect of systemic lidocaine on visceral and somatic nociception in conscious horses
AU2010257752B2 (en) Solid compositions comprising 5-aminolevulinic acid
EP1154768A1 (fr) Derive de gabapentin pour la prevention et le traitement de douleurs viscerales
JP2002500644A (ja) 子宮内化学的壊死化の方法、組成物、および装置
JP2011500711A (ja) 腸の下剤およびその使用
US20240350472A1 (en) Synergistic Compositions for Gynecological Procedures
Samour et al. Diagnosis and therapeutic management of trichomoniasis in falcons in Saudi Arabia
WO2002020005A1 (fr) Utilisation de l'arginine pour l'endoscopie et d'autres actes medicaux
ES2259299T3 (es) Uso de agentes de contraste en la fabricacion de agentes de diagnostico para la visualizacion del lumen intestinal.
Van Hoogmoed et al. Use of computed tomography to evaluate the intestinal tract of adult llamas
Lamazza et al. Effects of pinaverium bromide in the premedication of endoscopic retrograde cholangio-pancreatography and on motor activity of the sphincter of Oddi
JP3714972B2 (ja) 病変組織異常血管の注射用止血剤
Latorre et al. Double‐balloon enteroscopy in two dogs
Menzies‐Gow Diagnostic endoscopy of the urinary tract of the horse
US20250041329A1 (en) Acidic polymer compositions and methods of use thereof
KR102902906B1 (ko) 제자리에서 장 문합을 세척하기 위한 키트
Marušić et al. What is the right therapeutic approach to biliary choledochal cyst?
KR20260054694A (ko) 산성 중합체 조성물 및 이의 사용 방법
Starý et al. Corrosive injuries of the oesophagus and the stomach in children
US9155731B1 (en) Methods of non-gastrointestinal endoscopic procedures using L-hyoscyamine oral formulations
Blea et al. How to evaluate and treat ulceration of the glosso-epiglottic fold (subepiglottic area) in the standing horse.
Bohanon Colic in the equine neonate.
Mader Rabbit medicine for the small animal practitioner.
Dansereau et al. Scintigraphic study of oesophageal transit and retention
RU2432944C2 (ru) Способ профилактики послеоперационного спаечного процесса в брюшной полости

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP